| Event | Date |
|---|---|
| Open Date | 22-12-2025 , Monday |
| Close Date | 24-12-2025 , Wednesday |
| Tentative Allotment | 26-12-2025 , Friday |
| Tentative Listing Date | 30-12-2025 , Tuesday |
| Retail Appl. Cut Off Time | 24-12-2025 , Wednesday 05:00 PM |
| Non Retail Appl. Cut Off Time | 24-12-2025 , Wednesday 04:00 PM |
| Anchor Allotment | 19-12-2025 , Friday |
| Initiation Of Refund | 29-12-2025 , Monday |
| Credit Of Share To Demat | 29-12-2025 , Monday |
Gujarat Kidney and Super Speciality Limited is a regional healthcare company located in the central region of Gujarat. The company operates a chain of mid-sized multispeciality hospitals providing integrated healthcare services with a focus on secondary care and tertiary care.
The company provides healthcare services across general specialities and super-specialities, with a strong focus on renal sciences, urology, nephrology, renal transplant, cardiology, neurology, gastroenterology, oncology and other advanced surgical services.
Gujarat Kidney and Super Speciality Limited operates a regional hospital platform across Gujarat. Its healthcare network is focused on providing integrated treatment through multispeciality and super-speciality services. The company’s hospitals are located across Vadodara, Godhra, Bharuch, Anand and Borsad.
The company was built under the leadership of its Promoter and Managing Director, Dr. Pragnesh Yashwantsingh Bharpoda, who has more than a decade of experience in the medical industry and is an established name in the field of urology. He established the first hospital, Gujarat Kidney Hospital, in Vadodara in 2014 with a vision to provide quality healthcare services in central Gujarat.
The company operates and manages hospitals through the issuer entity, subsidiaries and controlled entities. Its network includes Gujarat Kidney and Superspeciality Hospital, Gujarat Multispeciality Hospital, Raj Palmland Hospital, Surya Hospital and ICU, Gujarat Surgical Hospital, Ashwini Medical Centre, Apex Multispeciality and Trauma Center, Ashwini Medical Store and four pharmacies operating within hospitals.
| Hospital / Entity | Relationship | Location | Total Bed Capacity | Approved Beds | Operational Beds | ICU and HDU Beds |
|---|---|---|---|---|---|---|
| Gujarat Kidney and Super Speciality Hospital | Issuer | Vadodara | 125 | 125 | 100 | 16 |
| Gujarat Multispeciality Hospital | Issuer | Godhra | 100 | 100 | 50 | 10 |
| Ashwini Medical Centre | Issuer | Anand | 50 | 25 | 25 | 11 |
| Raj Palmland Hospital Private Limited | Subsidiary | Bharuch | 50 | 30 | 30 | 10 |
| Harmony Medicare Private Limited | Subsidiary | Bharuch | 90 | 90 | 90 | 10 |
| Surya Hospital | Entity controlled by company | Borsad | 50 | 50 | 25 | 10 |
| Gujarat Surgical Hospital | Entity controlled by company | Vadodara | 25 | 25 | 20 | 5 |
Issuer means the hospital is directly operated under the IPO company. Subsidiary means the hospital is operated through a subsidiary company. Controlled entity means the company controls operations, but the ownership or structure may be different from direct ownership.
The company is not dependent on one hospital only. It has built a regional hospital platform across multiple cities. However, retail investors should understand the legal and operating structure because ownership, consolidation and control arrangements can affect financial reporting and future profitability.
The company’s overview and operational tables show different bed capacity figures, likely due to reporting basis, consolidation or acquisition inclusion. This should be read carefully from the RHP before making any investment view.
| Basis | Total Bed Capacity | Approved Bed Capacity | Operational Bed Capacity |
|---|---|---|---|
| Overview basis | 490 | 445 | 340 |
| Operational parameters table basis as of June 30, 2025 | 539 | 494 | 389 |
IPORupee View: For a hospital IPO, bed capacity is one of the most important operating metrics. Investors should check whether the number includes recently acquired hospitals, proforma consolidation or proposed acquisitions. A higher bed count is useful only when occupancy, revenue per occupied bed and doctor availability also improve.
Gujarat Kidney and Super Speciality Limited earns revenue mainly through hospital-based healthcare services. Its revenue comes from in-patient treatment, out-patient consultations, surgeries, ICU and critical care, diagnostics, pharmacy services, specialty and super-specialty services, government scheme patients, walk-in patients and individually insured patients.
Secondary services include surgical and general hospital services such as general surgery, laparoscopic surgery, orthopaedics, gynaecology and other hospital-based treatments.
Tertiary services include super-speciality services such as urology, nephrology, renal transplant, cardiology, neurology, neurosurgery, oncology and advanced procedures.
The company has a strong focus on kidney care, nephrology, urology and renal transplant. Gujarat Kidney Hospital is authorised to perform renal transplants and has conducted 31 renal transplants till date.
The company provides interventional cardiac procedures such as angiography and implantation of cardiac assist devices. Vadodara and Godhra locations support emergency response advantages.
The company offers treatment for stroke, brain haemorrhage, spinal disorders, neuro-oncology, epilepsy, trauma, brain tumours and minimally invasive neuro-spine procedures.
The hospital network provides gastroenterology services covering the digestive system, liver, pancreas, gallbladder and bile ducts, along with procedures such as endoscopy, ERCP and colonoscopy.
The company offers cancer-related services, including medical oncology and surgical oncology. Oncology can be a long-term demand area, but it requires strong clinical capability and patient trust.
The company has a broad service mix, but its strongest brand identity appears to be renal sciences and urology. This speciality-led positioning can help create local patient recall and referral strength.
The company has established urology sub-specialities such as endourology, urologic oncology, pediatric urology, reconstructive urology, renal transplant and laparoscopic urology.
| FY / Period | Endourology | Urologic Oncology | Pediatric Urology | Reconstructive Urology | Renal Transplant | Laparoscopic Urology |
|---|---|---|---|---|---|---|
| Three months ended June 30, 2025 | 212 | 17 | 6 | 6 | 1 | 18 |
| FY2025 | 850 | 65 | 25 | 24 | 5 | 65 |
| FY2024 | 838 | 58 | 23 | 24 | 27 | 59 |
| FY2023 | 840 | 60 | 24 | 23 | 2 | 60 |
| Total | 2,740 | 200 | 78 | 77 | 35 | 202 |
IPORupee View: Endourology is the largest procedure category and shows the company’s depth in urology-led procedures. Renal transplant numbers are lower and fluctuate, so investors should not treat transplant as the main volume driver. The broader renal and urology ecosystem is more important.
| Particulars | As of June 30, 2025 | As of March 31, 2025 | As of March 31, 2024 | As of March 31, 2023 |
|---|---|---|---|---|
| Total Bed Capacity | 539 | 539 | 539 | 439 |
| Approved Beds | 494 | 494 | 494 | 369 |
| Operational Beds | 389 | 389 | 389 | 339 |
| ICU Beds | 80 | 80 | 80 | 70 |
| IPD Volume | 3,240 | 13,281 | 12,733 | 11,238 |
| IPD Revenue | Rs. 2,185.65 lakhs | Rs. 8,172.11 lakhs | Rs. 7,194.18 lakhs | Rs. 6,274.02 lakhs |
| OPD Volume | 20,918 | 95,876 | 91,264 | 76,869 |
| OPD Revenue | Rs. 398.71 lakhs | Rs. 1,621.69 lakhs | Rs. 1,359.97 lakhs | Rs. 1,040.28 lakhs |
| Revenue from Operations | Rs. 3,109.01 lakhs | Rs. 11,997.46 lakhs | Rs. 10,344.15 lakhs | Rs. 8,579.19 lakhs |
| Bed Days Occupied | 19,440 | 79,686 | 76,398 | 67,428 |
| Average Bed Occupancy Rate | 54.77% | 56.12% | 53.81% | 54.49% |
| Average Revenue per Occupied Bed | Rs. 11,243.06 | Rs. 10,255.39 | Rs. 9,416.71 | Rs. 9,304.77 |
| Average Length of Stay | 6 days | 6 days | 6 days | 6 days |
IPD means In-Patient Department. These are patients admitted for surgery, ICU treatment, procedures or longer observation. IPD usually generates higher revenue because it includes room charges, surgery, nursing, diagnostics, ICU care and medicines.
OPD means Out-Patient Department. OPD patients visit for consultation, diagnosis, follow-up or minor treatment without admission. OPD is important because it can become the entry point for future admissions and surgeries.
Average bed occupancy remained stable but moderate, around 54% to 56%. This means there is room to improve utilisation. If occupancy improves without a proportionate rise in fixed costs, operating leverage can improve.
Average revenue per occupied bed improved from Rs. 9,304.77 in FY2023 to Rs. 10,255.39 in FY2025 and Rs. 11,243.06 for the three months ended June 30, 2025, showing better revenue intensity per occupied bed.
For the three months ended June 30, 2025, 94.54% of revenue from operations came from individually insured patients and walk-in patients. For FY2025, 90.00% of revenue from operations came from individually insured patients and walk-in patients.
IPORupee View: This is a positive signal because it shows local patient trust and reduces dependence on one single government scheme, corporate account or institutional tie-up. However, insured patient revenue still depends on claim approval, documentation, pricing agreements and settlement timelines.
The company also serves patients under Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana, public sector undertakings and private companies. These channels can support patient volume, especially in regional healthcare markets.
IPORupee View: Government scheme and institutional patients can increase volume, but reimbursement rates, claim approvals and payment cycles should be monitored because they can affect cash flows.
Restated consolidated financials reflect the company’s restated reporting basis. These numbers should not be mixed casually with the proforma numbers because the company has expanded through acquisitions.
| Particulars | Unit | Three months ended June 30, 2025 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| Revenue from Operations | Rs. in lakhs | 1,526.02 | 4,024.21 | 477.43 | - |
| EBITDA | Rs. in lakhs | 862.56 | 1,654.70 | 195.09 | -0.63 |
| EBITDA Margin | % | 56.52% | 41.12% | 40.86% | NA |
| PAT | Rs. in lakhs | 540.32 | 949.94 | 171.40 | -0.62 |
| PAT Margin | % | 35.41% | 23.61% | 35.90% | NA |
| Net Worth | Rs. in lakhs | 3,056.28 | 2,570.96 | 1,080.43 | 37.02 |
| Total Borrowings | Rs. in lakhs | 402.82 | 388.01 | 194.38 | 0.00 |
| Debt to Equity | Times | 0.13 | 0.15 | 0.18 | - |
| ROE | % | 15.85% | 36.61% | 15.86% | -1.67% |
| ROCE | % | 18.91% | 37.65% | 9.79% | -1.70% |
| Fixed Asset Turnover Ratio | Times | 0.80 | 2.00 | 0.50 | NA |
The proforma numbers present a broader view of the enlarged hospital network after considering acquisitions and consolidated operations. For a company growing through acquisitions, this basis is useful, but investors should still compare it with restated audited financials.
| Particulars | Unit | As of June 30, 2025 | As of March 31, 2025 | As of March 31, 2024 | As of March 31, 2023 |
|---|---|---|---|---|---|
| Revenue from Operations | Rs. in lakhs | 3,109.00 | 11,997.46 | 10,344.15 | 8,579.19 |
| EBITDA | Rs. in lakhs | 1,360.38 | 2,890.61 | 2,085.15 | 1,761.71 |
| EBITDA Margin | % | 43.76% | 24.09% | 20.16% | 20.53% |
| PAT | Rs. in lakhs | 835.47 | 1,513.16 | 996.94 | 635.46 |
| PAT Margin | % | 26.87% | 12.61% | 9.64% | 7.41% |
| Net Worth | Rs. in lakhs | 4,464.57 | 3,841.30 | 2,226.92 | 2,195.87 |
| Total Borrowings | Rs. in lakhs | 717.10 | 847.60 | 1,197.73 | 1,609.26 |
| Debt to Equity | Times | 0.15 | 0.22 | 0.54 | 0.73 |
| ROE | % | 16.79% | 38.38% | 43.49% | 30.22% |
| ROCE | % | 17.26% | 35.88% | 29.37% | 25.49% |
| Fixed Asset Turnover Ratio | Times | 1.08 | 4.06 | 4.44 | 2.71 |
The restated consolidated FY2025 revenue from operations is Rs. 4,024.21 lakhs, while the unaudited proforma consolidated FY2025 revenue from operations is Rs. 11,997.46 lakhs. This difference is large because the company has grown through acquisitions and proforma numbers present a broader view of the enlarged network.
Investors should not mix both numbers casually. Proforma numbers help understand the larger hospital network, but restated consolidated financials are important for legal and accounting comparison.
The company has expanded through acquisition and operational control of hospitals. Acquisition-led growth can provide faster access to hospital infrastructure, beds, doctors and local patient base, but it also creates integration risk.
The company acquired the hospital situated at Ashwini Medical Centre, Anand, on a slump sale basis. The sale deed for transfer of assets was entered on March 15, 2025. Approval is awaited to change the hospital name to Gujarat Kidney and Superspeciality Hospital, Anand.
The company entered into a Share Purchase Agreement dated October 3, 2025 with shareholders of Harmony Medicare Private Limited to acquire 100% equity share capital. It has completed acquisition of 51% equity shares.
The company is in the process of acquiring Parekhs Hospital at Ahmedabad. Parekhs Hospital was commissioned in 2006 and had 49 beds, including 8 ICU beds, as of February 28, 2025.
IPORupee View: Acquiring running hospitals can support faster expansion compared with building hospitals from scratch. But integration is critical. The company must retain doctors, align systems, maintain licenses, improve service quality, control costs and protect patient trust.
The company manages each hospital through a separate professional management team. Each hospital is managed by a Chief Operating Officer who supervises day-to-day functioning.
IPORupee View: This structure can help maintain operating control across multiple hospitals. For a hospital chain, hospital-level management is important because every hospital has daily operational needs such as patient admission, surgery scheduling, doctor coordination, billing, pharmacy, diagnostics, nursing, emergency care and compliance.
| Particulars | As of June 30, 2025 | As of March 31, 2025 | As of March 31, 2024 | As of March 31, 2023 |
|---|---|---|---|---|
| Doctors | 89 | 91 | 106 | 106 |
| Nurses | 332 | 303 | 306 | 309 |
| Other Staff | 338 | 354 | 372 | 288 |
For a hospital company, doctors and consultants are the real business strength. Beds alone do not create revenue. Patient inflow, surgeries and reputation depend heavily on doctors, nurses, medical staff, equipment and patient trust.
Doctor count declined from 106 in FY2023/FY2024 to 91 in FY2025 and 89 as of June 30, 2025. This should be monitored, although the company also has visiting consultants and full-time consultants on proforma basis.
The hospital sector is the core part of the Indian healthcare industry. The Indian hospital industry increased from approximately INR 2,400 billion in FY2016 to INR 5,800 billion in FY2023. It was estimated to have risen by 12% in FY2024 to approximately INR 6,496 billion.
Gujarat Kidney and Super Speciality Limited is positioned in the regional healthcare growth theme. Its presence in central Gujarat can be useful because many patients prefer quality healthcare closer to home.
The company has a strong identity in kidney care, urology, nephrology and renal sciences.
The company operates in multiple cities of Gujarat, giving local market understanding and patient reach.
The company offers both secondary and tertiary care services under one network.
High revenue from walk-in and individually insured patients indicates local trust and brand recall.
Revenue, EBITDA and PAT improved over FY2023 to FY2025 on a proforma consolidated basis.
Proforma debt-to-equity improved from 0.73 times in FY2023 to 0.22 times in FY2025.
Gujarat Kidney and Super Speciality Limited is a regional multispeciality hospital chain with a clear focus on renal sciences, urology and super-speciality healthcare services in Gujarat. The company has expanded from one hospital into a hospital network through acquisitions and operational control.
Its strengths include speciality-led positioning, regional healthcare presence, improving proforma financial performance, moderate leverage, walk-in patient trust and acquisition-led expansion. At the same time, the company should be analysed carefully because hospital businesses depend heavily on occupancy, doctor availability, clinical quality, reputation and integration of acquired facilities.
This is not a national hospital chain. It is a regional healthcare platform focused on Gujarat. Growth depends on execution in existing cities, patient inflow, doctor retention, acquisition integration and expansion into new Gujarat markets.
The company’s biggest speciality identity is kidney care and urology. Specialty-led hospitals often build stronger patient recall than generic hospitals, especially in regional markets.
The company has 389 operational beds as of June 30, 2025, but average occupancy is around 54% to 56%. If occupancy improves, operating leverage may improve. But occupancy improvement depends on doctors, service quality and local competition.
Average revenue per occupied bed increased from Rs. 9,304.77 in FY2023 to Rs. 10,255.39 in FY2025 and Rs. 11,243.06 for the three months ended June 30, 2025, indicating better revenue intensity.
Restated consolidated FY2025 revenue is Rs. 4,024.21 lakhs, while proforma FY2025 revenue is Rs. 11,997.46 lakhs. This difference is mainly due to acquisitions and enlarged network presentation.
Acquisition can expand the network faster, but success depends on retaining doctors, improving systems, maintaining service quality and integrating operations without hurting margins.
A high share of revenue from walk-in and individually insured patients suggests local patient trust and reduces dependence on one government scheme or one corporate client.
In hospital businesses, doctors and consultants drive patient inflow, surgery volumes and reputation. The company’s ability to attract and retain doctors will directly affect future performance.
Gujarat Kidney and Super Speciality Limited should be analysed as a regional hospital chain with a speciality-led healthcare model. The company has a clear focus on renal sciences and urology, and it is expanding through acquisitions.
Retail investors should not look only at the healthcare theme. They should check the company’s actual occupancy, revenue per occupied bed, doctor strength, acquisition integration, difference between restated and proforma financials, profitability, debt level and IPO valuation.
| Short Form | Full Form |
|---|---|
| ICU | Intensive Care Unit |
| HDU | High Dependency Unit |
| IPD | In-Patient Department |
| OPD | Out-Patient Department |
| ALOS | Average Length of Stay |
| ARPOB | Average Revenue Per Occupied Bed |
| IVF | In Vitro Fertilization |
| OBGY | Obstetrics and Gynaecology |
| ENT | Ear, Nose and Throat |
| VD | Venereal Disease |
| BPH | Benign Prostatic Hyperplasia |
| UTI | Urinary Tract Infection |
| ED | Erectile Dysfunction |
| ERCP | Endoscopic Retrograde Cholangiopancreatography |
| IBS | Irritable Bowel Syndrome |
| NCV | Nerve Conduction Velocity |
| EBITDA | Earnings Before Interest, Tax, Depreciation and Amortization |
| PAT | Profit After Tax |
| ROE | Return on Equity |
| ROCE | Return on Capital Employed |
| COO | Chief Operating Officer |
| SPA | Share Purchase Agreement |
| RHP | Red Herring Prospectus |
| PSU | Public Sector Undertaking |
This business overview and IPORupee insight is prepared only for educational and informational purposes based on IPO-related disclosures and information provided for understanding the company’s business model, operational profile and financial performance. It is not a recommendation to apply, avoid, buy, sell or hold any IPO or security.
IPORupee is not a SEBI-registered investment adviser, research analyst, broker or portfolio manager. Investors should read the Red Herring Prospectus, risk factors, financial statements, objects of the issue, peer comparison, valuation and official disclosures carefully and consult their financial advisor before making any investment decision.
| Category | Percentage | No. of Shares Offered | Amount |
|---|---|---|---|
QIB | 75.00 % | 1,65,00,000 | 188.10 Cr |
Retail | 10.00 % | 22,00,000 | 25.08 Cr |
Total HNI | 15.00 % | 33,00,000 | 37.62 Cr |
SHNI | 5.00 % | 11,00,000 | 12.54 Cr |
BHNI | 10.00 % | 22,00,000 | 25.08 Cr |
Gujarat Kidney and Super Speciality Ltd allotted 87,73,120 equity shares to anchor investors at ₹114 per share on 19 Dec 2025 before the IPO opening. The total anchor allocation stood at 100.01 Cr across 10 anchor investors.
The largest anchor investor received 35.00% of the anchor portion. The top five anchor investors together received 65,79,840 shares, representing about 75.00% of the total anchor allocation.
| Rank | Anchor Investor Name | Shares Allocated | Allocation % | Allocation Amount |
|---|---|---|---|---|
| 1 | CRAFT EMERGING MARKET FUND PCC-CITADEL CAPITAL FUND | 30,70,464 | 35.00 % | 35.00 Cr |
| 2 | KHANDELWAL FINANCE PRIVATE LIMITED | 13,16,096 | 15.00 % | 15.00 Cr |
| 3 | VENUS INVESTMENTS VCC - VENUS STELLAR FUND | 8,77,312 | 10.00 % | 10.00 Cr |
| 4 | CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND | 8,77,312 | 10.00 % | 10.00 Cr |
| 5 | NEXUS GLOBAL OPPORTUNITIES FUND | 4,38,656 | 5.00 % | 5.00 Cr |
The figures are based on the company’s stock exchange anchor allotment intimation. Anchor allocation is only an informational disclosure and does not indicate future listing performance.
| Application | Discount | Qty (Lot) | Total |
|---|---|---|---|
Retail MIN | - | 128 (1) | ₹ 14,592 |
Retail MAX | - | 1664 (13) | ₹ 1,89,696 |
SHNI MIN | - | 1792 (14) | ₹ 2,04,288 |
SHNI MAX | - | 8704 (68) | ₹ 9,92,256 |
BHNI MIN | - | 8832 (69) | ₹ 10,06,848 |
| Objective | No Of Shares | Amount |
|---|---|---|
Fresh Issue | 2,20,00,000 | 250.80 Cr |
| Name | Contact Person | Telephone | Website | |
|---|---|---|---|---|
Nirbhay Capital Services Pvt Ltd | Kunjal Soni | +91 79 48970649 | kunjal@nirbhaycapital.com | www.nirbhaycapital.com |
Understand company details, IPO size, price band, lot size, exchange listing, fresh issue and Offer for Sale (OFS) in simple language for retail investors.
This IPO is of Gujarat Kidney and Super Speciality Ltd. The issue is scheduled to open on Monday, 22 December 2025 and closes on Wednesday, 24 December 2025.
After the IPO process is completed, the shares are proposed to be listed on both NSE and BSE.
IPO size means the total amount the company plans to raise through the public issue.
For Gujarat Kidney and Super Speciality Ltd IPO, the total issue size is Rs 250.8 crore, consisting of a fresh issue of Rs 250.8 crore.
Price band is the price range within which investors can bid for shares in a book-built IPO.
For this IPO, the lower price band is Rs 108 per share and the upper price band is Rs 114 per share.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Gujarat Kidney and Super Speciality Ltd IPO, the minimum lot size is 128 shares. At the upper price band of Rs 114 per share, the minimum application amount is Rs 14,592. Applications must be made in multiples of 128 shares.
Fresh Issue means the company issues new shares to investors and receives money from that part of the IPO.
For Gujarat Kidney and Super Speciality Ltd IPO, the Fresh Issue size is Rs 250.8 crore. The company can use these funds for purposes mentioned in the IPO documents, such as business growth, repayment of borrowings, working capital, capital expenditure, or general corporate purposes.
Understand the important IPO dates, allotment process, refund schedule and listing timeline in a retail-friendly format.
The IPO opening date is the first day on which investors can apply for the public issue.
For Gujarat Kidney and Super Speciality Ltd IPO, the IPO opens on Monday, 22 December 2025.
The IPO closing date is the last day on which investors can submit, modify, or cancel their IPO applications.
Gujarat Kidney and Super Speciality Ltd IPO closes on Wednesday, 24 December 2025.
The tentative allotment date is the expected date on which the registrar finalizes the share allotment for valid IPO applications.
For Gujarat Kidney and Super Speciality Ltd IPO, the tentative allotment date is Friday, 26 December 2025.
The tentative listing date is the expected date on which IPO shares begin trading on the stock exchanges.
Gujarat Kidney and Super Speciality Ltd IPO is expected to list on Tuesday, 30 December 2025.
After allotment, funds are unblocked or refunds are initiated for non-allotted investors, while allotted shares are credited to investors' demat accounts before listing.
For Gujarat Kidney and Super Speciality Ltd IPO, refund initiation is expected on Monday, 29 December 2025, and credit of shares to demat accounts is expected on Monday, 29 December 2025.
Understand IPO category-wise reservation, QIB quota, retail quota, HNI allocation, shareholder reservation and the meaning of structure columns in a simple format.
IPO structure shows how shares are divided among different categories of investors, such as QIB, Retail, NII/HNI, Employees, and Shareholders.
For Gujarat Kidney and Super Speciality Ltd IPO, the available categories in the structure table include QIB, Retail, Non-Institutional Investors (NII/HNI). The NII/HNI category includes SHNI and BHNI sub-categories. Investors can use this table to understand category-wise allocation before applying.
QIB stands for Qualified Institutional Buyers. This category includes mutual funds, banks, insurance companies, and other large financial institutions.
In Gujarat Kidney and Super Speciality Ltd IPO, 75% shares are reserved under the QIB category, with 1,65,00,000 shares offered, and an allocation amount of ₹188.10 crore.
The Retail category is reserved for individual investors and HUFs applying for up to Rs 2 lakh within the retail investment limit allowed under IPO rules.
In Gujarat Kidney and Super Speciality Ltd IPO, 10% shares are reserved under the Retail category, with 22,00,000 shares offered, and an allocation amount of ₹25.08 crore.
NII/HNI stands for Non-Institutional Investors / High Net-Worth Individuals. This category generally includes investors applying for more than Rs 2 lakh, above the retail investment limit.
In Gujarat Kidney and Super Speciality Ltd IPO, 15% shares are reserved under the NII/HNI category, with 33,00,000 shares offered, and an allocation amount of ₹37.62 crore.
SHNI stands for Small HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 2 lakh but not exceeding Rs 10 lakh.
In Gujarat Kidney and Super Speciality Ltd IPO, 5% shares are reserved under the SHNI sub-category, with 11,00,000 shares offered, and an allocation amount of ₹12.54 crore.
BHNI stands for Big HNI. It is a sub-category within the NII/HNI category and generally refers to applications for more than Rs 10 lakh.
In Gujarat Kidney and Super Speciality Ltd IPO, 10% shares are reserved under the BHNI sub-category, with 22,00,000 shares offered, and an allocation amount of ₹25.08 crore.
Understand retail lot size, HNI application limits, employee category, shareholder category and investment amount calculations using the IPO lot table.
Lot size is the minimum number of shares an investor must apply for in an IPO. IPO applications are usually made in fixed lot multiples.
For Gujarat Kidney and Super Speciality Ltd IPO, the minimum lot size is 128 shares. At the upper price band of Rs 114 per share, the minimum application amount is Rs 14,592. Applications must be made in multiples of 128 shares.
Retail minimum application shows the minimum application size for retail investors.
For Gujarat Kidney and Super Speciality Ltd IPO, the Retail minimum application is 128 shares (1 lot) for about Rs 14,592.
Retail maximum application shows the maximum application size generally available under the retail category.
For Gujarat Kidney and Super Speciality Ltd IPO, the Retail maximum application is 1,664 shares (13 lots) for about Rs 1,89,696.
SHNI minimum application shows the minimum application size for the Small HNI category.
For Gujarat Kidney and Super Speciality Ltd IPO, the SHNI minimum application is 1,792 shares (14 lots) for about Rs 2,04,288.
SHNI maximum application shows the maximum application size available under the Small HNI category, when provided.
For Gujarat Kidney and Super Speciality Ltd IPO, the SHNI maximum application is 8,704 shares (68 lots) for about Rs 9,92,256.
BHNI minimum application shows the minimum application size for the Big HNI category.
For Gujarat Kidney and Super Speciality Ltd IPO, the BHNI minimum application is 8,832 shares (69 lots) for about Rs 10,06,848.
Understand important financial figures in simple language using the financial statement data available for the IPO.
Financial Highlights show important numbers from the company's financial statements. These may include income, expenses, profit, assets, liabilities, cash flow and other financial information, depending on the data available for the IPO.
The table displays available financial data based on the IPO information currently available. Fields may differ from company to company depending on disclosures and reporting format.
Investors should read the table to understand the company's financial performance and financial position over different periods.
The table may help users review income, expenses, profitability, balance sheet position, cash movement or other financial information, depending on the available data.
Financial statement line items may differ because companies operate in different industries and may follow different reporting formats.
Some companies may provide detailed financial breakup, while others may present broader financial categories.
Investors should review income, expenses, profitability, debt position, asset base, liabilities and cash flow position together.
A single financial figure should not be used alone to judge the company.
Profit is important, but it does not show the full financial picture.
Investors should also review revenue quality, expenses, debt, assets, liabilities, cash flow, valuation and business risks.
Cash flow helps investors understand how money moves in and out of the business.
A company may report profit but still face cash flow pressure, so cash flow should be reviewed along with profit, debt and balance sheet information.
No. Financial Highlights are useful, but investors should also review valuation, peer comparison, KPI data, business risks, IPO pricing, management discussion and official offer documents such as the RHP or DRHP.
Understand how the company may be compared with similar businesses using the peer comparison data available for the IPO.
Peer Comparison means comparing the IPO company with businesses operating in a similar sector or industry.
It helps investors understand the company in a broader industry context.
Peer Comparison helps investors understand how the company can be compared with similar businesses using available financial or valuation metrics.
It is useful for context, but it should not be treated as a final investment conclusion.
Peer comparison metrics may differ depending on the companies selected, accounting format, business model and available public information.
Investors should compare only relevant and similar metrics.
Investors should use the peer comparison table as a reference point.
Available metrics should be read together with business model, scale, profitability, margins, debt, growth, valuation and IPO pricing.
No. Peer Comparison does not directly decide whether an IPO is good or bad.
It only provides context for comparison. Final analysis should include financial statements, KPI data, valuation, risk factors and official offer documents.
No. Peer Comparison is only one part of IPO analysis.
Investors should also review financial statements, KPI data, business risks, valuation, IPO pricing and company fundamentals.
Understand important KPI metrics in simple language using the key performance indicator data available for the IPO.
Key Performance Indicators, or KPIs, are financial and valuation metrics used to understand profitability, efficiency, leverage, return-based ratios and earnings performance.
They help investors understand the company beyond basic financial figures.
KPIs help investors assess profitability, capital efficiency, leverage, valuation and earnings quality.
They should be reviewed together with financial statements, peer comparison and IPO pricing.
KPI data may differ depending on the company, industry, financial disclosures and available offer document information.
Not every IPO may provide every KPI, and some metrics may not be applicable to every business.
Investors should read KPI metrics together instead of relying on one ratio.
A single KPI may not give the full picture unless it is reviewed with financial statements, peer comparison, business model and valuation.
No. High or low KPI values need context.
The meaning of a ratio may differ depending on industry, business model, debt level, growth stage, profitability and IPO valuation.
No. KPI data is useful, but it should not be used alone.
Investors should also review financial statements, peer comparison, business risks, valuation, IPO pricing and official offer documents such as the RHP or DRHP.